Inhibiting mtDNA transcript translation alters Alzheimer's disease‐associated biology
Authors:
Open Access
- 23 October 2024
- journal article
- research article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (12) , 8429-8443
Abstract
INTRODUCTION: Alzheimer's disease (AD) features changes in mitochondrial structure and function. Investigators debate where to position mitochondrial pathology within the chronology and context of other AD features.METHODS: To address whether mitochondrial dysfunction alters AD‐implicated genes and proteins, we treated SH‐SY5Y cells and induced pluripotent stem cell (iPSC)‐derived neurons with chloramphenicol, an antibiotic that inhibits mtDNA‐generated transcript translation. We characterized adaptive, AD‐associated gene, and AD‐associated protein responses.RESULTS: SH‐SY5Y cells and iPSC neurons responded to mtDNA transcript translation inhibition by increasing mtDNA copy number and transcription. Nuclear‐expressed respiratory chain mRNA and protein levels also changed. There were AD‐consistent concordant and model‐specific changes in amyloid precursor protein, beta amyloid, apolipoprotein E, tau, and α‐synuclein biology.DISCUSSION: Primary mitochondrial dysfunction induces compensatory organelle responses, changes nuclear gene expression, and alters the biology of AD‐associated genes and proteins in ways that may recapitulate brain aging and AD molecular phenomena.Highlights: In AD, mitochondrial dysfunction could represent a disease cause or consequence. We inhibited mitochondrial translation in human neuronal cells and neurons. Mitochondrial and nuclear gene expression shifted in adaptive‐consistent patterns. APP, Aβ, APOE, tau, and α‐synuclein biology changed in AD‐consistent patterns. Mitochondrial stress creates an environment that promotes AD pathology.Keywords
Funding Information
- Royal Historical Society (P30AG072973, R01AG061194, R01AG060733)
- Thompson Foundation
- National Institute on Aging (T32AG078114)
This publication has 74 references indexed in Scilit:
- Genetic and multi‐omic risk assessment of Alzheimer's disease implicates core associated biological domainsAlzheimer's & Dementia: Translational Research & Clinical Interventions, 2024
- Dementia with Lewy bodies: Impact of co‐pathologies and implications for clinical trial designAlzheimer's & Dementia, 2022
- The role of mitochondrial genome abundance in Alzheimer's diseaseAlzheimer's & Dementia, 2022
- Mitochondrial DNA copy number in human disease: the more the better?FEBS Letters, 2020
- Alzheimer’s Disease Pathologic Cascades: Who Comes First, What Drives WhatNeurotoxicity Research, 2011
- The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementiaActa Neuropathologica, 2010
- Measuring and Increasing Protein SolubilityJournal of Pharmaceutical Sciences, 2008
- Alzheimer's disease cybrids replicate ?-amyloid abnormalities through cell death pathwaysAnnals of Neurology, 2000
- Qualitative and Quantitative Changes in Skeletal Muscle mtDNA and Expression of Mitochondrial-Encoded Genes in the Human Aging ProcessBiochemical and Molecular Medicine, 1997
- Amyloid deposition as the central event in the aetiology of Alzheimer's diseaseTrends in Pharmacological Sciences, 1991